FINWIRES · TerminalLIVE
FINWIRES

Koryx Copper Maintained at Buy at Stifel Canada Following Haib Copper Project Update; Price Target Kept at C$4.50

By

Stifel Canada on Thursday maintained its buy rating on the shares of Koryx Copper (KRY.V) and its C$4.50 price target after the company released an update on work at its Haib Copper Project in Namibia.

"Recent metallurgical optimization work continues to improve the Haib development case ahead of the planned 4Q26 PFS. Ore sorting and coarse particle flotation test work supports higher feed grades, increased throughput and a simplified flowsheet, which will likely result in a value-accretive PFS by year-end 2026. These initiatives support our view that Haib has the potential to produce ~120ktpa copper production during the first 10 years and have a mine life exceeding 30 years. Koryx currently trades at 0.25x spot P/NAV vs peers at 0.31x," analyst Cole McGill wrote.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $3.42, Change: $+0.04, Percent Change: +1.18%

Related Articles

Research

Update: BofA Securities Upgrades UnitedHealth to Buy From Neutral, $450 Price Target

(Updated to include BofA's commentary)BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improvement and "supportive" near-term data points form a favorable Q2.If utilization trends continue to moderate, the brokerage believes the company-given its bellwether status-should lead a broader MCO rally, analysts led by Kevin Fischbeck wrote in a Thursday note.UnitedHealth has an average rating of overweight and mean price target of $404.44, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $399.70, Change: $+22.70, Percent Change: +6.02%

$UNH
Research

DPM Metals Kept at Buy at Stifel Canada Following Chelopech Drill Results; Price Target Kept at C$61.00

Stifel Canada on Thursday reiterated its buy rating on the shares of DPM Metals (DPM.TO) and its C$61.00 price target after the company released exploration results from the Chelopech Mine in Bulgaria."Recent exploration success at Chelopech continues to demonstrate the potential for mine-life extension and future growth beyond current reserves. DPM's May 2026 Wedge Zone Deep (WZD) drilling defined a high-grade mineralized system ~250m below current Mineral Reserves, highlighted by 58m @ 14.58g/t Au (versus current Chelopech reserve grade of 2.18g/t Au), with an initial resource estimate expected by YE26. The newly announced Brevene South Porphyry (BSP) discovery identified a separate gold-copper porphyry system within the Chelopech concession, highlighted by 398m @ 3.00g/t AuEq (within 713m @ 2.52g/t AuEq). Together, WZD and BSP represent opportunities for reserve growth at an operation that recently extended mine life to 2036. DPM trades at 0.70x LT Stifel P/NAV vs peers at 0.53x. While both discoveries remain too early stage to incorporate into our valuation framework, continued drilling and resource delineation could support incremental NAV growth and further extend Chelopech's long-term production profile," analyst Cole McGill wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $47.97, Change: $+0.54, Percent Change: +1.14%

$DPM.TO
Research

Correction: B. Riley Downgrades Anterix to Buy From Neutral, Adjusts Price Target to $69 From $44

(Corrects to include rating change in headline.)(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ATEX